Elicera Therapeutics AB Cash Flow Conversion Efficiency
Elicera Therapeutics AB cash flow conversion efficiency. Based on the latest financial reports, Elicera Therapeutics AB (ELIC) has a cash flow conversion efficiency ratio of -0.156x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.74 Million ≈ $-509.90K USD) by net assets (Skr30.33 Million ≈ $3.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Elicera Therapeutics AB (2017–2024)
Cash flow conversion efficiency of Elicera Therapeutics AB from 2017 to 2024. This chart illustrates how Elicera Therapeutics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Elicera Therapeutics AB stock price today for real-time trading data and today's change.
Elicera Therapeutics AB Cash Flow Conversion Ratio Explained
Elicera Therapeutics AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Elicera Therapeutics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elicera Therapeutics AB ranked by their cash flow conversion efficiency. Also see market cap of Elicera Therapeutics AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dantax
CO:DANT
|
-0.091x |
|
Thanasiri Group Public Company Limited
BK:THANA
|
0.024x |
|
HK Co. Ltd
KQ:044780
|
0.021x |
|
Samil Co.Ltd
KQ:032280
|
0.015x |
|
Vision Sigma
TA:VISN
|
-0.017x |
|
City Steel Public Company Limited
BK:CITY
|
0.004x |
|
S. Pack & Print Public Company Limited
BK:SPACK
|
0.013x |
|
Swoop Holdings Ltd
AU:SWP
|
-0.066x |
Annual Cash Flow Conversion Efficiency for Elicera Therapeutics AB (2017–2024)
The table below shows the annual cash flow conversion efficiency of Elicera Therapeutics AB from 2017 to 2024. Review how much free cash does Elicera Therapeutics AB generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr20.77 Million ≈ $2.24 Million |
Skr-23.46 Million ≈ $-2.53 Million |
-1.130x | -24.16% |
| 2023-12-31 | Skr16.40 Million ≈ $1.77 Million |
Skr-14.92 Million ≈ $-1.61 Million |
-0.910x | -248.18% |
| 2022-12-31 | Skr32.80 Million ≈ $3.53 Million |
Skr-8.57 Million ≈ $-922.36K |
-0.261x | +4.50% |
| 2021-12-31 | Skr52.24 Million ≈ $5.62 Million |
Skr-14.29 Million ≈ $-1.54 Million |
-0.274x | -209.39% |
| 2020-12-31 | Skr10.24 Million ≈ $1.10 Million |
Skr-905.25K ≈ $-97.42K |
-0.088x | +77.29% |
| 2019-12-31 | Skr614.10K ≈ $66.09K |
Skr-239.16K ≈ $-25.74K |
-0.389x | -31.11% |
| 2018-12-31 | Skr805.16K ≈ $86.65K |
Skr-239.16K ≈ $-25.74K |
-0.297x | -0.44% |
| 2017-12-31 | Skr808.69K ≈ $87.03K |
Skr-239.16K ≈ $-25.74K |
-0.296x | -- |
About Elicera Therapeutics AB
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing EL… Read more